These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31043655)

  • 1. Combination of Repurposed Drug Diosmin with Amoxicillin-Clavulanic acid Causes Synergistic Inhibition of Mycobacterial Growth.
    Pushkaran AC; Vinod V; Vanuopadath M; Nair SS; Nair SV; Vasudevan AK; Biswas R; Mohan CG
    Sci Rep; 2019 May; 9(1):6800. PubMed ID: 31043655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Long Does Antimycobacterial Antibiotic-loaded Bone Cement Have In Vitro Activity for Musculoskeletal Tuberculosis?
    Lee JH; Han CD; Cho SN; Yang IH; Lee WS; Baek SH; Shin JW; Husein KEI; Park KK
    Clin Orthop Relat Res; 2017 Nov; 475(11):2795-2804. PubMed ID: 28795294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ertapenem and Faropenem against Mycobacterium tuberculosis: in vitro testing and comparison by macro and microdilution.
    Gonzalo X; Satta G; Ortiz Canseco J; McHugh TD; Drobniewski F
    BMC Microbiol; 2020 Aug; 20(1):271. PubMed ID: 32867678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
    Cavanaugh JS; Jou R; Wu MH; Dalton T; Kurbatova E; Ershova J; Cegielski JP;
    J Antimicrob Chemother; 2017 Jun; 72(6):1678-1687. PubMed ID: 28333192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
    Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
    Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibilities of nontuberculosis mycobacterial species to amoxicillin-clavulanic acid alone and in combination with antimycobacterial agents.
    Utrup LJ; Moore TD; Actor P; Poupard JA
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1454-7. PubMed ID: 7492084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of TB-E12 as a novel FtsZ inhibitor with anti-tuberculosis activity.
    Lin Y; Zhang H; Zhu N; Wang X; Han Y; Chen M; Jiang J; Si S
    Tuberculosis (Edinb); 2018 May; 110():79-85. PubMed ID: 29779778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis.
    Bergmann JS; Woods GL
    Int J Tuberc Lung Dis; 1998 Aug; 2(8):621-6. PubMed ID: 9712275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerotiorin inhibits protein kinase G from Mycobacterium tuberculosis and impairs mycobacterial growth in macrophages.
    Chen D; Ma S; He L; Yuan P; She Z; Lu Y
    Tuberculosis (Edinb); 2017 Mar; 103():37-43. PubMed ID: 28237032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug repurposing: Fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization - Insight from DFT calculations, molecular docking and molecular dynamics simulations.
    Akinpelu OI; Lawal MM; Kumalo HM; Mhlongo NN
    Tuberculosis (Edinb); 2020 Mar; 121():101920. PubMed ID: 32279872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
    Rani C; Mehra R; Sharma R; Chib R; Wazir P; Nargotra A; Khan IA
    Tuberculosis (Edinb); 2015 Dec; 95(6):664-677. PubMed ID: 26318557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic characterization of Mycobacterium tuberculosis reveals potential targets of bostrycin.
    Yuan P; He L; Chen D; Sun Y; Ge Z; Shen D; Lu Y
    J Proteomics; 2020 Feb; 212():103576. PubMed ID: 31706025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel acetohydroxyacid synthase inhibitors as active agents against Mycobacterium tuberculosis by virtual screening and bioassay.
    Wang D; Zhu X; Cui C; Dong M; Jiang H; Li Z; Liu Z; Zhu W; Wang JG
    J Chem Inf Model; 2013 Feb; 53(2):343-53. PubMed ID: 23316686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis.
    Nguyen PC; Delorme V; Bénarouche A; Guy A; Landry V; Audebert S; Pophillat M; Camoin L; Crauste C; Galano JM; Durand T; Brodin P; Canaan S; Cavalier JF
    Bioorg Chem; 2018 Dec; 81():414-424. PubMed ID: 30212765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
    Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing.
    Dwivedi M; Mukhopadhyay S; Yadav S; Dubey KD
    Comput Biol Med; 2022 Jul; 146():105607. PubMed ID: 35617724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
    Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
    Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.